JAMA Oncology Author Interviews JAMA Network
-
- Health & Fitness
Interviews with authors of articles from JAMA Oncology. JAMA Oncology is the definitive journal for scientists, clinicians, and trainees in the field of oncology worldwide. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.
-
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
Interview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD.
Related Content:
T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy -
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
Interview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD.
Related Content:
Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time -
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer
Interview with José P. Leone, MD, author of Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer. Hosted by Nora L. (Mary) Disis, MD.
Related Content:
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor–Positive Breast Cancer -
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Interview with Sajid A. Khan, MD, author of Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. Hosted by Mary L. (Nora) Disis, MD.
Related Content:
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US -
Atezolizumab in Combination With Carboplatin in Metastatic TNBC
Interview with Jennifer A. Pietenpol, PhD, Brian D. Lehmann, PhD, and Vandana G. Abramson, MD, authors of Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. Hosted by Mary L. (Nora) Disis, MD.
Related Content:
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer -
Shorter-Course Radiotherapy for Prostate Cancer
Interview with Daniel E. Spratt, MD, author of Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer. Hosted by Jack West, MD.
Related Content:
Increasing Use of Shorter-Course Radiotherapy for Prostate Cancer